The use of the humanized monoclonal anti–programmed cell death 1 antibodies pembrolizumab and nivolumab as potent anticancer therapies is rapidly increasing. However, since their approval, numerous cases of cutaneous reactions have been reported. Cutaneous adverse reactions to these agents have yet to be fully characterized and range from nonspecific eruptions to recognizable skin manifestations, which may be localized and vary from mild to life threatening. This systematic review article provides an overview of the various adverse cutaneous reactions to pembrolizumab and nivolumab therapy and offers suggestions for their management.Le texte complet de cet article est disponible en PDF.
Key words : anti–PD-1, cutaneous adverse reaction, dermatology, immunotherapy, oncology
Abbreviations used : anti–PD-1, PD-L1, TEN
| Funding sources: None.
| Conflicts of interest: None disclosed.
| IRB approval status: Not applicable.
| Reprints are not available from the authors.